Limits...
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: The impact of psoriasis varies with the body region affected. In addition, patients have different perceptions of disease improvement and treatment satisfaction based on the location of skin clearance with treatment. The monoclonal antibody secukinumab selectively targets interleukin-17A—a central cytokine of psoriasis—and provides rapid and sustained clearance for moderate-to-severe psoriasis affecting all body regions. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the trunk, upper limbs, and lower limbs.

Methods: Data were pooled from four phase 3 studies. To be included in the analysis for each body region, patients were required to have a Psoriasis Area and Severity Index (PASI) score ≥12 for that body region and psoriasis covering ≥10% of the surface area of that region. Secukinumab was administered at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48.

Results: Across the trunk, upper limbs, and lower limbs, initial PASI subscore responses were sustained to Week 52. At Week 52, trunk (T) PASI 90/100 responses were achieved by 78.4%/71.1% of patients receiving secukinumab 300 mg, respectively, and by 66.3%/56.9% of patients receiving secukinumab 150 mg, respectively. At Week 52, upper limb (UL) PASI 90/100 responses were achieved by 67.3%/59.1% of patients receiving secukinumab 300 mg, respectively, and by 50.3%/43.3% of patients receiving secukinumab 150 mg, respectively. At Week 52, lower limb (LL) PASI 90/100 responses were achieved by 63.9%/55.3% of patients receiving secukinumab 300 mg, respectively, and by 45.1%/36.4% of patients receiving secukinumab 150 mg, respectively. A 50% reduction in mean PASI subscore occurred after 2.8, 2.9, and 3.4 weeks with secukinumab 300 mg on the trunk, upper limbs, and lower limbs, respectively.

Conclusion: Secukinumab provided robust and sustained efficacy for moderate-to-severe psoriasis affecting the trunk, upper limbs, and lower limbs.

Funding: Novartis Pharmaceuticals Corporation.

Trial registration: ClinicalTrials.gov identifiers: NCT01365455, NCT01358578, NCT01555125, and NCT01636687.

No MeSH data available.


Related in: MedlinePlus

PASI 90 subscore response rates by body region. Missing values were imputed by multiple imputation. Clinical response rates for a trunk, b upper limbs, and c lower limbs from Baseline to Week 52. n Represents the number of evaluable subjects. PASI 90 90% improvement from Baseline Psoriasis Area and Severity Index
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC5120629&req=5

Fig1: PASI 90 subscore response rates by body region. Missing values were imputed by multiple imputation. Clinical response rates for a trunk, b upper limbs, and c lower limbs from Baseline to Week 52. n Represents the number of evaluable subjects. PASI 90 90% improvement from Baseline Psoriasis Area and Severity Index

Mentions: PASI 90 and PASI 100 subscore response rates to Week 52 for each body region are shown in Figs. 1 and 2, respectively. For all body regions, initial PASI 90 and PASI 100 subscore responses were maintained to Week 52. At Week 16, a numerically greater proportion of patients achieved skin clearance on the trunk than on the upper limbs or the lower limbs. Trunk (T) PASI 90 and TPASI 100 responses were achieved by 82.5% and 70.0% of patients receiving secukinumab 300 mg, respectively, and by 70.8% and 58.9% of patients receiving secukinumab 150 mg, respectively. Upper limb (UL) PASI 90 and ULPASI 100 responses were achieved by 72.1% and 61.4% of patients receiving secukinumab 300 mg, respectively, and by 57.6% and 43.7% of patients receiving secukinumab 150 mg, respectively. Lower limb (LL) PASI 90 and LLPASI 100 responses were achieved by 68.9% and 52.9% of patients receiving secukinumab 300 mg, respectively, and by 50.5% and 35.8% of patients receiving secukinumab 150 mg, respectively.Fig. 1


Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
PASI 90 subscore response rates by body region. Missing values were imputed by multiple imputation. Clinical response rates for a trunk, b upper limbs, and c lower limbs from Baseline to Week 52. n Represents the number of evaluable subjects. PASI 90 90% improvement from Baseline Psoriasis Area and Severity Index
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC5120629&req=5

Fig1: PASI 90 subscore response rates by body region. Missing values were imputed by multiple imputation. Clinical response rates for a trunk, b upper limbs, and c lower limbs from Baseline to Week 52. n Represents the number of evaluable subjects. PASI 90 90% improvement from Baseline Psoriasis Area and Severity Index
Mentions: PASI 90 and PASI 100 subscore response rates to Week 52 for each body region are shown in Figs. 1 and 2, respectively. For all body regions, initial PASI 90 and PASI 100 subscore responses were maintained to Week 52. At Week 16, a numerically greater proportion of patients achieved skin clearance on the trunk than on the upper limbs or the lower limbs. Trunk (T) PASI 90 and TPASI 100 responses were achieved by 82.5% and 70.0% of patients receiving secukinumab 300 mg, respectively, and by 70.8% and 58.9% of patients receiving secukinumab 150 mg, respectively. Upper limb (UL) PASI 90 and ULPASI 100 responses were achieved by 72.1% and 61.4% of patients receiving secukinumab 300 mg, respectively, and by 57.6% and 43.7% of patients receiving secukinumab 150 mg, respectively. Lower limb (LL) PASI 90 and LLPASI 100 responses were achieved by 68.9% and 52.9% of patients receiving secukinumab 300 mg, respectively, and by 50.5% and 35.8% of patients receiving secukinumab 150 mg, respectively.Fig. 1

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: The impact of psoriasis varies with the body region affected. In addition, patients have different perceptions of disease improvement and treatment satisfaction based on the location of skin clearance with treatment. The monoclonal antibody secukinumab selectively targets interleukin-17A—a central cytokine of psoriasis—and provides rapid and sustained clearance for moderate-to-severe psoriasis affecting all body regions. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the trunk, upper limbs, and lower limbs.

Methods: Data were pooled from four phase 3 studies. To be included in the analysis for each body region, patients were required to have a Psoriasis Area and Severity Index (PASI) score ≥12 for that body region and psoriasis covering ≥10% of the surface area of that region. Secukinumab was administered at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48.

Results: Across the trunk, upper limbs, and lower limbs, initial PASI subscore responses were sustained to Week 52. At Week 52, trunk (T) PASI 90/100 responses were achieved by 78.4%/71.1% of patients receiving secukinumab 300 mg, respectively, and by 66.3%/56.9% of patients receiving secukinumab 150 mg, respectively. At Week 52, upper limb (UL) PASI 90/100 responses were achieved by 67.3%/59.1% of patients receiving secukinumab 300 mg, respectively, and by 50.3%/43.3% of patients receiving secukinumab 150 mg, respectively. At Week 52, lower limb (LL) PASI 90/100 responses were achieved by 63.9%/55.3% of patients receiving secukinumab 300 mg, respectively, and by 45.1%/36.4% of patients receiving secukinumab 150 mg, respectively. A 50% reduction in mean PASI subscore occurred after 2.8, 2.9, and 3.4 weeks with secukinumab 300 mg on the trunk, upper limbs, and lower limbs, respectively.

Conclusion: Secukinumab provided robust and sustained efficacy for moderate-to-severe psoriasis affecting the trunk, upper limbs, and lower limbs.

Funding: Novartis Pharmaceuticals Corporation.

Trial registration: ClinicalTrials.gov identifiers: NCT01365455, NCT01358578, NCT01555125, and NCT01636687.

No MeSH data available.


Related in: MedlinePlus